Zomig Nasal Spray
Migraines' Brain Changes Not Linked to Mental Harm »
"Nov. 13, 2012 -- Women who get migraines are more likely than those who don't to develop small areas of tissue changes in their brains, a new study shows. At the same time, these changes do not seem to affect the women's thinking or memory.
"...Read the Migraines' Brain Changes Not Linked to Mental Harm article »
Zomig Nasal Spray
OVERDOSE
There is no experience with acute overdose. Clinical study subjects receiving single 50 mg oral doses of zolmitriptan commonly experienced sedation.
The elimination half-life of ZOMIG is 3 hours [see CLINICAL PHARMACOLOGY] and therefore monitoring of patients after overdose with ZOMIG (zolmitriptan nasal spray) should continue for at least 15 hours or while symptoms or signs persist.
There is no specific antidote to zolmitriptan. In cases of severe intoxication, intensive care procedures are recommended, including establishing and maintaining a patent airway, ensuring adequate oxygenation and ventilation, and monitoring and support of the cardiovascular system. It is unknown what effect hemodialysis or peritoneal dialysis has on the plasma concentrations of zolmitriptan.
CONTRAINDICATIONS
Ischemic or Vasospastic Coronary Artery Disease
ZOMIG (zolmitriptan nasal spray) should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's variant angina, or other significant underlying cardiovascular disease [see WARNINGS AND PRECAUTIONS].
Cerebrovascular Syndromes
ZOMIG (zolmitriptan nasal spray) should not be given to patients with cerebrovascular syndromes including (but not limited to) stroke of any type as well as transient ischemic attacks. [see WARNINGS AND PRECAUTIONS].
Peripheral Vascular Disease
ZOMIG (zolmitriptan nasal spray) should not be given to patients with peripheral vascular disease including (but not limited to) ischemic bowel disease [see WARNINGS AND PRECAUTIONS].
Uncontrolled Hypertension
Because ZOMIG (zolmitriptan nasal spray) may increase blood pressure, it should not be given to patients with uncontrolled hypertension [see WARNINGS AND PRECAUTIONS].
Use within 24 hours of treatment with another 5-HT1 agonist, or ergotamine-containing medication, or ergot-type medication
ZOMIG (zolmitriptan nasal spray) and any ergotamine-containing or ergot-type medication (such as dihydroergotamine or methysergide) should not be used within 24 hours of each other, nor should ZOMIG (zolmitriptan nasal spray) and another 5-HT1 agonist be used within 24 hours of each other [see DRUG INTERACTIONS].
Hemiplegic or Basilar Migraine
ZOMIG (zolmitriptan nasal spray) should not be administered to patients with hemiplegic or basilar migraine.
Administration of MAO-A inhibitors within 2 weeks
Concurrent administration of MAO-A inhibitors or use of zolmitriptan within 2 weeks of discontinuation of MAO-A inhibitor therapy is contraindicated [see CLINICAL PHARMACOLOGY and DRUG INTERACTIONS].
Hypersensitivity to zolmitriptan
ZOMIG is contraindicated in patients who are hypersensitive to zolmitriptan or any of its inactive ingredients.
Last reviewed on RxList: 12/22/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Zomig Nasal Spray Information
Zomig Nasal Spray - User Reviews
Zomig Nasal Spray User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Here is a collection of user reviews for the medication Zomig Nasal Spray sorted by most helpful.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Living Better
Find the secrets to longer life.
Updated & New
